PME is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts. The magazine provides insights and offers solutions to the issues that keep industry leaders awake at night.
From the latest developments in cancer treatments and the strategies behind them to new marketing and commercialisation models and the regulations that underpin the fabric of the sector – PME's got it covered.
PME is a trusted source for decision makers and influencers in pharma and healthcare who, through the practical and accessible content, have the knowledge to tackle whatever comes their way.
mRNA-1010 generated a strong immune response against all four WHO-recommended flu strains
The supply of cisplatin, carboplatin and methotrexate has nearly halved in the past year
The drugmaker expects to expand its research pipeline from six to 12 over next 18 months
The study will evaluate the ability of MSCopilot to identify early signs of disability worsening
Reimagining medical communicationsBy Jeremy Williams
Medical communications: connecting the dots from data to changeBy Cathy Chow
The importance of accelerating clinical trial diversity多样性不应该是一个事后的想法——这是一个我nvestment in the credibility of scientific endeavour
Point.1 – HCP data with purpose and perceptionBy Phil Streit and Sarah Price
eCTD 4.0 is changing the regulatory landscape – what you need to knowAll regions that have published guidelines will mandate implementation of eCTD version 4.0 by 2028, with more regions to follow in the future
Pharmaceutical Market Europe - September 2023
Accelerating clinical trial diversity; the fight against AMR; innovation in chronic diseases; the importance of actinic keratosis awareness
Pharmaceutical Market Europe (PME) magazine is also available on the iPhone/iPad as afree app
Wright first joined the group in 2007 as general manager of Publicis Resolute
No results were found
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
